Abstract
Persistent pain, a common clinical condition, could be caused by inflammation, tissue injury secondary to trauma or surgery, and nerve injuries. It is often inadequately controlled by current treatments, such as opioids and nonsteroidal anti-inflammatory drugs. The PDZ (Postsynaptic density 95, Discs large, and Zonula occludens-1) domains are ubiquitous protein interaction modules often found among multi-protein signaling complexes at neuronal synapses. Recent preclinical research shows that targeted disruption of PDZ domain-mediated protein interaction among N-methyl-Daspartate (NMDA) receptor signaling complexes significantly attenuates the development and maintenance of persistent pain without affecting nociceptive responsiveness to acute pain. PDZ domains at excitatory synapses may be new molecular targets for prevention and treatment of persistent pain. Here, we illustrate expression and distribution of the PDZ domain- containing proteins associated with NMDA receptors in the pain-related regions of the central nervous system, review the evidence for their roles in persistent pain states, and discuss potential mechanisms by which these PDZ domaincontaining proteins are involved in persistent pain.
Keywords: PSD-93, PSD-95, NMDA receptors, AMPA receptors, Trafficking, Spinal cord, Persistent pain, Chronic pain
Current Neuropharmacology
Title: PDZ Domains at Excitatory Synapses: Potential Molecular Targets for Persistent Pain Treatment
Volume: 4 Issue: 3
Author(s): Yuan-Xiang Tao and Roger A. Johns
Affiliation:
Keywords: PSD-93, PSD-95, NMDA receptors, AMPA receptors, Trafficking, Spinal cord, Persistent pain, Chronic pain
Abstract: Persistent pain, a common clinical condition, could be caused by inflammation, tissue injury secondary to trauma or surgery, and nerve injuries. It is often inadequately controlled by current treatments, such as opioids and nonsteroidal anti-inflammatory drugs. The PDZ (Postsynaptic density 95, Discs large, and Zonula occludens-1) domains are ubiquitous protein interaction modules often found among multi-protein signaling complexes at neuronal synapses. Recent preclinical research shows that targeted disruption of PDZ domain-mediated protein interaction among N-methyl-Daspartate (NMDA) receptor signaling complexes significantly attenuates the development and maintenance of persistent pain without affecting nociceptive responsiveness to acute pain. PDZ domains at excitatory synapses may be new molecular targets for prevention and treatment of persistent pain. Here, we illustrate expression and distribution of the PDZ domain- containing proteins associated with NMDA receptors in the pain-related regions of the central nervous system, review the evidence for their roles in persistent pain states, and discuss potential mechanisms by which these PDZ domaincontaining proteins are involved in persistent pain.
Export Options
About this article
Cite this article as:
Tao Yuan-Xiang and Johns A. Roger, PDZ Domains at Excitatory Synapses: Potential Molecular Targets for Persistent Pain Treatment, Current Neuropharmacology 2006; 4 (3) . https://dx.doi.org/10.2174/157015906778019473
DOI https://dx.doi.org/10.2174/157015906778019473 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Oxidative Stress-Induced Caspases are Regulated in Human Myeloid HL-60 Cells by Calcium Signal
Current Signal Transduction Therapy Brain Perfusion In Sepsis
Current Vascular Pharmacology Recent Advancement in Computer-Aided Drug Design
Current Pharmaceutical Design Experimental Drugs for Neuropathic Pain
Current Neuropharmacology Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome
Current Drug Safety Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms
Current Neuropharmacology Recent Updates on Biological Activities of Oxadiazoles
Mini-Reviews in Medicinal Chemistry Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors
Current Drug Metabolism Abnormal Functional and Structural Asymmetry as Biomarker for Schizophrenia
Current Topics in Medicinal Chemistry Selective Modulators of α<sub>5</sub>-Containing GABA<sub>A</sub> Receptors and their Therapeutic Significance
Current Drug Targets Targeting Glia Cells: Novel Perspectives for the Treatment of Neuropsychiatric Diseases
Current Neuropharmacology Triheptanoin Supplementation to Ketogenic Diet Curbs Cognitive Impairment in APP/PS1 Mice Used as a Model of Familial Alzheimer’s Disease
Current Alzheimer Research Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Recent Patents and Discovery of Anti-inflammatory Agents from Marine Source
Recent Patents on Inflammation & Allergy Drug Discovery Common Mechanisms of Excitatory and Inhibitory Imbalance in Schizophrenia and Autism Spectrum Disorders
Current Molecular Medicine Neuronal Excitability in Epileptogenic Zones Regulated by the Wnt/ Β-Catenin Pathway
CNS & Neurological Disorders - Drug Targets Closed-loop Neuropharmacology for Epilepsy: Distant Dream or Future Reality?
Current Neuropharmacology Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Effects of Nucleosides on Glia - Neuron Interactions Open up New Vistas in the Development of More Effective Antiepileptic Drugs
Current Medicinal Chemistry